Sunday, Nov. 12, 2017
Online webcast
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The SITC Annual Meeting is supported in part by grants from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dendreon Pharmaceuticals North America LLC, Genentech, Incyte Corporation, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., and Prometheus Laboratories Inc., and Regeneron Pharmaceuticals, Inc.
Target AudienceSession: Genetically Modified Cell TherapyThe audience includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This includes, but is not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.
Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy? Physicians, cancer immunologists, registered nurses, pharmacists, statisticians, physicists, scientists, bioengineers and mathematicians.
Educational ObjectivesUpon completion of this meeting, participants will be able to:
- Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
- Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
- Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention
Faculty
Session: Genetically Modified Cell TherapyCo-Chairs:
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Carl H. June, MD – University of Pennsylvania
Helen E. Heslop, MD – Baylor College of Medicine
Gene Edited CAR T CellsMartin Pule, PhD –
University College LondonUpdates in CAR T cellsCrystal L. Mackall, MD –
Stanford University
Genetically Modified T Cells for Solid TumorsStephen Gottschalk, MD –
St. Jude Children's Research Hospital
Late-Breaking: CD19 CAR Enter the MainstreamJennifer Brogdon –
Novartis Institute of Biomedical Research
Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cellsAngela Boroughs, BS –
Massachusetts General Hospital, Harvard University
Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T CellsMargot Pont, PhD –
Fred Hutchinson Cancer Research Center
Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy? Co-Chairs:
Howard Kaufman, MD, FACS – Replimune Group, Inc.
Herbert Levine, PhD – Rice University
Overview of the Immunotherapy FieldFrancesco M. Marincola, MD –
AbbVie Inc.Emerging TopicsThomas F. Gajewski, MD, PhD –
University of ChicagoChallenges in Clinical DevelopmentMichael Postow, MD –
Memorial Sloan Kettering Cancer CenterSystems of Biology Modeling of the Immune SystemDoron Levy, PhD –
University of MarylandT Cell RepertoireCurtis Callan, PhD –
Princeton UniversityModeling the Fitness Costs of NeoantigensBenjamin Greenbaum, PhD –
Tisch Cancer InstituteProgram Agenda
Session: Genetically Modified Cell Therapy
8:05 – 8:30 a.m.
|
Gene Edited CAR T Cells Martin Pule, PhD – University College London
|
8:30 – 8:55 a.m.
|
Updates in CAR T cells Crystal L. Mackall, MD – Stanford University
|
8:55 – 9:20 a.m.
|
Genetically Modified T Cells for Solid Tumors Stephen Gottschalk, MD – St. Jude Children's Research Hospital
|
9:20 – 9:45 a.m.
|
Late-Breaking: CD19 CAR Enter the Mainstream Jennifer Brogdon – Novartis Institute of Biomedical Research
|
9:45 – 10 a.m.
|
Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cells Angela Boroughs, BS – Massachusetts General Hospital, Harvard University
|
10 – 10:15 a.m.
|
Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T Cells Margot Pont, PhD – Fred Hutchinson Cancer Research Center
|
Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?
10:30 – 10:35 a.m.
|
Welcome and Introductions
|
10:35 – 10:55 a.m.
|
Overview of the Immunotherapy Field Francesco M. Marincola, MD – AbbVie Inc.
|
10:55 – 11:15 a.m.
|
Emerging Topics Thomas F. Gajewski, MD, PhD – University of Chicago
|
11:15 – 11:35 a.m.
|
Challenges in Clinical Development Michael Postow, MD – Memorial Sloan Kettering Cancer Center
|
11:35 – 11:55 a.m.
|
Systems of Biology Modeling of the Immune System Doron Levy, PhD – University of Maryland
|
11:55 – 12:15 p.m.
|
T Cell Repertoire Curtis Callan, PhD – Princeton University
|
12:15 – 12:35 p.m.
|
Modeling the Fitness Costs of Neoantigens Benjamin Greenbaum, PhD – Tisch Cancer Institute
|
12:35 – 1 pm.
|
Panel Discussion
|
Physician Continuing Medical EducationThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 4.0
AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 4.0 contact hour(s) (0.40 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Numbers:
- 0809-9999-17-652-L01-P, 2.0 hours, Genetically Modified Cell Therapy
- 0809-9999-17-739-L01-P, 2.0 hours, Hot Topic Symposium
Type of Activity: Knowledge
Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.Continuing Nursing EducationThe Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 4.0 contact hour(s) is provided by the Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
Disclosure of Conflicts of InterestPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Martin Pule, PhDDr. Pule has nothing to disclose.
Crystal L. Mackall, MDConsulting fees from Adaptimmune, GSK, Roche, Unum Therapeutics, Vore Pharmaceuticals.
Contracted research from Bluebird Bio.Ownership interest from Juno Therapeutics.
Stephen Gottschalk, MDContracted research from Tessa Therapuetics.
Jennifer BrogdonRoyalty from Novartis.
Ownership interest from Novartis.
Angela Boroughs, BSMs. Boroughs has nothing to disclose.
Margot Pont, PhDDr. Pont has nothing to disclose.
Francesco Marincola, MDDr. Marincola has nothing to disclose.
Thomas F. Gajewski, MD, PhDReceipt of intellectual property rights/patent holder from Evelo, Aduro.
Consulting fees from Aduro, Jounce, Merck, Roche/Genentech, FogPharma.
Contracted research from BMS, Merck, Roche/Genentech, Ono, Seattle Genetics.
Ownership interest from Jounce.
Michael Postow, MDDr. Postow has nothing to disclose.
Curtis Callan, PhDDr. Callan has nothing to disclose.
Doron Levy, PhDDr. Levy has nothing to disclose.
Benjamin Greenbaum, PhDDr. Greenbaum has nothing to disclose.
Planners and ManagersMarcela V. Maus, MD, PhDConsulting fees from Adaptimmune, Adaptive Biotechnologies, Agenus, Bluebird Bio, Cell Design Labs, Cellectis (SAB), CRISPR Therapeutics, Kite Pharma, Neon, Obsidian, Unum, TCR2 (SAB) and WindMIL (SAB).
Contracted research from Agenus, CRISPR Therapeutics, Kyn, TCR2, Unum.
Carl H. June, MDRoyalty from Novartis.
Contracted research from Novartis.
Ownership interest from Tmunity Therapeutics.
Helen E. Heslop, MDReceipt of intellectual property rights/patent holder from Cell Medica.
Consulting fees from Novartis.
Contracted research from Cell Medica.
Ownership interest from Viracyte, Marker Therapeutics.
Howard Kaufman, MD, FACSSalary from Compass Therapeutics.
Consulting fees from Amgen, Celldex, EMD Serono, Merck, Prometheus, Turnstone Biologics.
Contracted research from Viralytics.
Herbert Levine, PhDDr. Levine has nothing to disclose.
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
The following SITC planners and managers: Kathryn Agard, CMP; Clarissa Barnes; KathrynBehling; Esther Berkowitz, MBChB, MA; Nadine Couto, CMP; Jody Felski; Julie Frinzi; CariGrulke, CMP; Peter Intile, PhD; Erin Irelan; Angela Kilbert; Sara Krizan; Mindon Laue, MA;Claire Leischer, MS; Kim Mitschke; Nichole Nikolic; Erin Pacheco; Andrew Palios; Andrea Rindo;Sharon Rise, MA; Alicia Schuessler, CAE; Jacqueline Smith, MA, MS; Angie Squiers; RosanneStelpflug, MS; Shelby Stone; Donnette Tinsley, MsEd; Lianne Wiggins; Adam Wise; and AliyaZouine have nothing to disclose.
Tara Withington, CAE, Executive Director of SITC, has ownership interest as a partner at Executive Director, Inc.
Disclosure of Unlabeled UseThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
How to Obtain CreditPlease go online to CME University at: www.cmeuniversity.com and register or login (takes less than 1 minute).Once logged into CME University, follow these steps:
- Click on “Find Post-Test/Evaluation by Course” at the top of the page.
- Type in “13035” and hit enter.
- Click on title when it appears.
- Choose your profession/type of credit you are seeking.
- Complete the online Evaluation Form.
Upon completion of the online Evaluation form, you will have immediate access to a certificate of attendance to print or save for your files. Pharmacists have up to 30 days to submit.If you have any questions regarding the CME certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.